Repligen Corp (NASDAQ: RGEN) is a bioprocessing equipment and consumables company that makes products used in the manufacturing of biological drugs. It generates revenue by selling systems, single-use consumables, and instruments to biopharmaceutical manufacturers across upstream and downstream drug production processes. Repligen operates as a single bioprocessing business segment organized into four product franchises: Filtration (including Fluid Management), Chromatography, Process Analytics, and Proteins. The company has built its portfolio through internal development and targeted acquisitions since 2012, accumulating over 40 years of industry history. Corporate headquarters are in Waltham, Massachusetts, with 19 manufacturing sites, the majority in the United States, and additional sites in Estonia, France, Germany, Ireland, the Netherlands, Sweden, and Taiwan. The filing notes historical reliance on a limited number of large customers as a material revenue risk. Repligen does not pay dividends based on the filing's risk and capital structure disclosures.

Revenue model

Product revenue from selling bioprocessing systems, single-use consumables, and instruments to biopharmaceutical manufacturers. Revenue is transactional, with an installed-base consumables component tied to systems sold.

Products and services

Filtration: XCell ATF Cell Retention Systems, KrosFlo TFF tangential flow filtration systems, hollow fiber filter consumables, ProConnex fluid management flowpaths, bags, tubing, valves, totes, carts, and mixers (including ProConnex MixOne RG-X launched 2025). Chromatography: OPUS Pre-Packed Columns (single-use, resin-agnostic), KRM Chromatography Systems. Process Analytics: PATsmart SoloVPE and SoloVPE PLUS slope spectroscopy systems (launched 2025), PATsmart FlowVPX inline concentration measurement systems. Proteins franchise also disclosed but not detailed in excerpts.

Customers and end markets

Biopharmaceutical and biological drug manufacturers using upstream and downstream bioprocessing. End markets include process development, clinical-scale manufacturing, and commercial-scale biological drug production. Filing discloses historical reliance on a limited number of large customers as a material concentration risk.

Value-chain role

Upstream and downstream bioprocessing equipment and consumables supplier. Sits between raw material suppliers and drug manufacturers, providing the tools and single-use hardware that enable biologics production at laboratory through commercial scale.

Geographic exposure

Headquarters in Waltham, Massachusetts. Manufacturing in the United States (California, Massachusetts, New Hampshire, New Jersey, New York) and internationally in Estonia, France, Germany, Ireland, the Netherlands, Sweden, and Taiwan. Filing notes foreign currency exchange rate exposure as a material risk.

Source: SEC 10-K, filed 2026-02-26

Industry: Biological Products, (No Diagnostic Substances) Peers: Avantor Inc Bio Rad Laboratories Inc Bio-Techne Corp Bruker Corp Charles River Laboratories International Inc Revvity Inc Syneos Health, Inc. Maravai LifeSciences Holdings Inc Thermo Fisher Scientific Inc Waters Corp